Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genprex Inc
(NQ:
GNPX
)
2.614
+0.174 (+7.13%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Genprex Inc
< Previous
1
2
3
4
Next >
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $7.5M Registered Direct Offering
July 24, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $7.5M Registered Direct Offering
July 19, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh
July 18, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Genprex Inc.’s (NASDAQ: GNPX) Inspiring Patient Video on Gene Therapy’s Potential in NSCLC Treatment
June 02, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline
July 17, 2023
Via
Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience
July 10, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Unique Treatment Paradigm Featured in Bell2Bell Podcast
July 06, 2023
Via
Investor Brand Network
Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3
July 06, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Chinese Patent, Exclusivity for REQORSA(R) Gene Therapy Combination in Many of the Largest Markets
July 05, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives Fast Track Designation for Proprietary Immunogene Therapy
June 28, 2023
Via
Investor Brand Network
Exposures
Product Safety
Genprex Inc. (NASDAQ: GNPX) CMO Discusses Recent Company Announcements in Bell2Bell Podcast Episode
June 23, 2023
Via
Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) CMO Video Discusses Advances in Company’s Fight Against Tumors
June 20, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape
June 16, 2023
Via
Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Announces Positive Data From Phase 1 Clinical Trial Evaluating REQORSA(R) Immunogene Therapy for Late-Stage Non-Small Cell Lung Cancer
June 14, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Chief Medical Officer Featured Guest on Latest Bell2Bell Release
June 08, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Eyes Broad-Based Application Potential of ONCOPREX(R) Nanoparticle Delivery System
June 07, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Video Featuring Clinical Trial Patient Sharing Study Experience
June 02, 2023
Via
Investor Brand Network
Genprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical Trial
June 02, 2023
Via
ACCESSWIRE
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives SRC Approval to Advance to Phase 2 Portion of REQORSA(R) Clinical Trial
May 30, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Results of Phase 1 Clinical Trial Will Be Published at ASCO Meeting
May 26, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data with NPRL2 Gene Therapy
May 23, 2023
Via
Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting
May 17, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate and Present at Upcoming May Industry and Investor Conferences
May 08, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Data Supporting Therapeutic Potential of Its Non-Viral Delivery System
April 19, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Research Findings, Additional Support for REQORSA(R) and Its Therapeutic Potential
April 18, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Statement Regarding FDA Initiative to Accelerate Approval Process for Gene Therapies
March 23, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Barcelona Conference
March 13, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Management to Participate in Two Upcoming Conferences
March 08, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $4M Registered Direct Offering
February 27, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Inks Deal with University of Pittsburgh for Exclusive License to Diabetes Technology
January 05, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.